Journal of Gastrointestinal Surgery

, Volume 14, Supplement 1, pp 75–80 | Cite as

Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors

  • Daniel Vallböhmer
  • Jan Brabender
  • Ralf Metzger
  • Arnulf H. Hölscher
DeMeester Festschrift



Esophageal adenocarcinoma is the most rapidly increasing cancer in Western countries. Like esophageal squamous-cell carcinoma, these tumors are often detected at an advanced stage, requiring a multimodal concept. Despite improvements in detection, surgical resection, and (neo-) adjuvant therapy, the overall survival of esophageal cancer remains lower than other solid tumors. In fact, just 30–40% of the patients with advanced esophageal cancer benefit from a neoadjuvant therapy. Therefore, predictive/prognostic markers are needed to allow tailored multimodality therapy with increased efficacy.


In recent years, there has been an exponential growth in our understanding of the cellular and molecular events associated with cell cycle regulation, programmed cell death, angiogenesis, and tumor growth. In this review, the classification of Hanahan and Weinberg is used concerning the six essential changes in carcinogenesis, i.e., the six hallmarks of cancer: (1) self-sufficiency in growth signals; (2) insensitivity to antigrowth signals; (3) avoidance of apoptosis; (4) limitless replicative potential; (5) sustained angiogenesis; and (6) tissue invasion and metastasis.


According to these six steps, this review provides an update of the most recent data about predictive/prognostic molecular markers in patients with esophageal cancer.


Esophageal adenocarcinoma Neoadjuvant therapy Predictive/prognostic molecular markers 


  1. 1.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi:10.3322/canjclin.57.1.43.CrossRefPubMedGoogle Scholar
  2. 2.
    Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:112–127.PubMedGoogle Scholar
  3. 3.
    Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.PubMedCrossRefGoogle Scholar
  4. 4.
    Ando N, Ozawa S, Kitagawa Y et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–232. doi:10.1097/00000658-200008000-00013.CrossRefPubMedGoogle Scholar
  5. 5.
    Whooley BP, Law S, Murthy SC et al. Analysis of reduced death and complication rates after esophageal resection. Ann Surg. 2001;233:338–344. doi:10.1097/00000658-200103000-00006.CrossRefPubMedGoogle Scholar
  6. 6.
    Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729–746. doi:10.1016/S0039-6109(02)00029-4.CrossRefPubMedGoogle Scholar
  7. 7.
    Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–234. doi:10.1016/S1470-2045(07)70039-6.CrossRefPubMedGoogle Scholar
  8. 8.
    Greer SE, Goodney PP, Sutton JE et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172–177. doi:10.1016/j.surg.2004.06.033.CrossRefPubMedGoogle Scholar
  9. 9.
    Zacherl J, Sendler A, Stein HJ et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067–1074.PubMedGoogle Scholar
  10. 10.
    Brucher BL, Stein HJ, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963–971.PubMedGoogle Scholar
  11. 11.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-9.CrossRefPubMedGoogle Scholar
  12. 12.
    Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett’s-associated neoplasia: correlation with prognosis. Mod Pathol. 1997;10:105–112.PubMedGoogle Scholar
  13. 13.
    Inada S, Koto T, Futami K et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29:493–503. doi:10.1007/BF02482343.CrossRefPubMedGoogle Scholar
  14. 14.
    Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8:448–453. doi:10.1016/j.gassur.2004.01.006.CrossRefPubMedGoogle Scholar
  15. 15.
    Gibault L, Metges JP, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107–115. doi:10.1038/sj.bjc.6602625.CrossRefPubMedGoogle Scholar
  16. 16.
    Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391–395. doi:10.1016/j.ijrobp.2007.07.2325.PubMedGoogle Scholar
  17. 17.
    Polkowski W, van Sandick JW, Offerhaus GJ et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1999;6:290–297. doi:10.1007/s10434-999-0290-2.CrossRefPubMedGoogle Scholar
  18. 18.
    Brien TP, Odze RD, Sheehan CE et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35–39. doi:10.1016/S0046-8177(00)80195-1.CrossRefPubMedGoogle Scholar
  19. 19.
    Aloia TA, Harpole DH Jr, Reed CE et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001;72:859–866. doi:10.1016/S0003-4975(01)02838-7.CrossRefPubMedGoogle Scholar
  20. 20.
    Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91:666–672.PubMedGoogle Scholar
  21. 21.
    Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:1323–1327. doi:10.1016/S0360-3016(03)00782-X.PubMedGoogle Scholar
  22. 22.
    Kuwahara M, Hirai T, Yoshida K et al. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus. 1999;12:116–119. doi:10.1046/j.1442-2050.1999.00034.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999;57:311–317. doi:10.1159/000012067.CrossRefPubMedGoogle Scholar
  24. 24.
    Ikeda G, Isaji S, Chandra B et al. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999;86:1396–1405. doi:10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO;2-H.CrossRefPubMedGoogle Scholar
  25. 25.
    Sturm I, Petrowsky H, Volz R et al. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001;19:2272–2281.PubMedGoogle Scholar
  26. 26.
    Brock MV, Gou M, Akiyama Y et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912–2919.PubMedGoogle Scholar
  27. 27.
    Shimada Y, Watanabe G, Yamasaki S et al. Histological response of cisplatin predicts patients’ survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer. 2000;36:987–993. doi:10.1016/S0959-8049(00)00049-6.CrossRefPubMedGoogle Scholar
  28. 28.
    Nakashima S, Natsugoe S, Matsumoto M et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 2000;20:1933–1937.PubMedGoogle Scholar
  29. 29.
    Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110:838–844. doi:10.1002/ijc.20215.CrossRefPubMedGoogle Scholar
  30. 30.
    Takayama T, Nagao M, Sawada H et al. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol. 2001;78:116–123. doi:10.1002/jso.1130.CrossRefPubMedGoogle Scholar
  31. 31.
    Raouf AA, Evoy DA, Carton E et al. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003;16:17–23. doi:10.1046/j.1442-2050.2003.00281.x.CrossRefPubMedGoogle Scholar
  32. 32.
    Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med. 2001;7:413–417.PubMedGoogle Scholar
  33. 33.
    Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95. doi:10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9.CrossRefPubMedGoogle Scholar
  34. 34.
    Vallböhmer D, Kuhn E, Warnecke-Eberz U et al. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2008;9:681–690. doi:10.2217/14622416.9.6.681.CrossRefPubMedGoogle Scholar
  35. 35.
    Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer. 1998;83:652–659. doi:10.1002/(SICI)1097-0142(19980815)83:4<652::AID-CNCR4>3.0.CO;2-M.CrossRefPubMedGoogle Scholar
  36. 36.
    Lord RVN, Salonga D, Danenberg KD et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4:135–142. doi:10.1016/S1091-255X(00)80049-9.CrossRefPubMedGoogle Scholar
  37. 37.
    Vallböhmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg. 2006;141:476–481. doi:10.1001/archsurg.141.5.476.CrossRefPubMedGoogle Scholar
  38. 38.
    Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104. doi:10.1002/jso.20070.CrossRefPubMedGoogle Scholar
  39. 39.
    Kuo KT, Chow KC, Wu YC. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg. 2003;76:909–914. doi:10.1016/S0003-4975(03)00717-3.CrossRefPubMedGoogle Scholar
  40. 40.
    Takatori H, Natsugoe S, Okumura H et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008;34:397–402. doi:10.1016/j.ejso.2007.04.011.PubMedGoogle Scholar
  41. 41.
    Han B, Liu J, Ma MJ, Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol. 2005;11:2188–2192.PubMedGoogle Scholar
  42. 42.
    Barclay C, Li AW, Geldenhuys L et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res. 2005;11:7683–7691. doi:10.1158/1078-0432.CCR-05-0771.CrossRefPubMedGoogle Scholar
  43. 43.
    Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg. 2002;21:657–663. doi:10.1016/S1010-7940(02)00044-1.CrossRefPubMedGoogle Scholar
  44. 44.
    Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002;86:552–557. doi:10.1038/sj.bjc.6600129.CrossRefPubMedGoogle Scholar
  45. 45.
    Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004;127:1579–1586. doi:10.1016/j.jtcvs.2003.12.034.CrossRefPubMedGoogle Scholar
  46. 46.
    Xi H, Baldus SE, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res. 2005;11:8341–8347. doi:10.1158/1078-0432.CCR-04-2373.CrossRefPubMedGoogle Scholar
  47. 47.
    Krishnadath KK, Tilanus HW, van BM et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997;182:331–338. doi:10.1002/(SICI)1096-9896(199707)182:3<331::AID-PATH860>3.0.CO;2-D.CrossRefPubMedGoogle Scholar
  48. 48.
    Murray GI, Duncan ME, O_Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998;185:256–261. doi:10.1002/(SICI)1096-9896(199807)185:3<256::AID-PATH115>3.0.CO;2-A.CrossRefPubMedGoogle Scholar
  49. 49.
    Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;67:300–309. doi:10.1159/000081331.CrossRefPubMedGoogle Scholar
  50. 50.
    Tanioka Y, Yoshida T, Yagawa T et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–2121. doi:10.1038/sj.bjc.6601372.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2009

Authors and Affiliations

  • Daniel Vallböhmer
    • 1
  • Jan Brabender
    • 1
  • Ralf Metzger
    • 1
  • Arnulf H. Hölscher
    • 1
  1. 1.Department of General, Visceral and Cancer SurgeryUniversity of CologneCologneGermany

Personalised recommendations